Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment.

ABSTRACT:

Introduction

Alzheimer's disease (AD) is characterized by the deposition of tau and amyloid in the brain. Although the core cerebrospinal fluid (CSF) AD biomarkers amyloid β peptide 1-42 (Aβ1-42), total tau (t-tau) and phosphorylated tau 181 (p-tau181) show good diagnostic sensitivity and specificity, additional biomarkers that can aid in preclinical diagnosis or better track disease progression are needed. Activation of the complement system, a pivotal part of inflammation, occurs at very early stages in the AD brain. Therefore, CSF levels of complement proteins that could be linked to cognitive and structural changes in AD may have diagnostic and prognostic value.

Methods

Using xMAP® technology based assays we measured complement 3 (C3) and factor H (FH) in the CSF of 110

SUBMITTER: Toledo JB 

PROVIDER: S-EPMC4255518 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature